Eli Lilly’s weight loss and diabetes drug tops Keytruda
Digest more
Lilly now says it expects non-GAAP earnings from $23 to $23.70 a share this year, up from $21.75 to $23. The new guidance is ...
Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.
(Reuters) -Eli Lilly said on Wednesday it will invest more than $1.2 billion to expand its manufacturing site in Puerto Rico, ...
AstraZeneca, Eli Lilly and Merck committed $120 million to develop an advanced pharmaceutical manufacturing training center in Central Virginia.
Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...
Eli Lilly’s stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback